Research ArticleBeta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over study
Introduction
In patients with cirrhosis, repeated large-volume paracentesis associated with plasma expansion is the first-line treatment of refractory ascites [1], [2]. However, large-volume paracentesis has been shown to trigger a circulatory dysfunction syndrome, characterized by systemic vasodilation and a decrease in effective arterial blood volume despite a compensatory increase in cardiac output [3], [4], [5], [6], [7]. Patients who develop post-paracentesis circulatory dysfunction (PICD) are at risk of developing hyponatremia and renal impairment, and have a low probability of survival [3]. Non-selective beta-blockers are frequently administered to patients with cirrhosis for the prevention of gastrointestinal hemorrhage secondary to portal hypertension [8], [9], [10]. However, in an observational prospective study, we recently reported that beta-blockers were associated with poor survival in these patients, suggesting that this pharmacological treatment has deleterious effects in patients with ascites treated by large-volume paracentesis [11]. Although the mechanism responsible for these deleterious effects is unknown, beta-blockers may play a role in the development of the PICD. Before to evaluate the incidence of PICD in patients randomized into a group that stays under beta-blockers and into a group in whom the beta-blockers are withdrawn, the incidence of PICD was assessed before and after discontinuation of beta-blockers in patients with cirrhosis and refractory ascites. Thus, we decided to perform a prospective cross-over study in these patients.
Section snippets
Patients
Patients with cirrhosis being treated with non-selective beta-blockers, for the prevention of bleeding, and admitted for refractory ascites were consecutively included in this study. The definition of refractory ascites was based on International Ascites Club criteria [12]. Patients were considered to have refractory ascites when they had either diuretic-resistant or diuretic-intractable ascites. Refractory ascites were qualified as diuretic-resistant when ascites could not be stabilized
Patient characteristics
Twenty consecutive patients with cirrhosis, referred to our Liver Unit for large-volume paracentesis, were prospectively evaluated. Ten patients were not included: nine patients refused to provide written consent, and one patient was lost to follow-up. Ten patients were included, six with diuretic-resistant ascites and four with diuretic-intractable ascites. Baseline patient clinical characteristics are summarized in Table 1. There was no significant difference before and after propranolol
Discussion
In this series of patients with cirrhosis and refractory ascites, mean survival and the probability of survival were similar to those observed in previous studies [13], [14]. All patients had at least two paracenteses per month for at least 3 months confirming the diagnosis of refractory ascites and the need for therapeutic or large volume paracentesis associated with plasma expansion [6].
Removal of large volumes of ascites by paracentesis may have deleterious effects on circulatory function
Conflict of interest
The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
References (17)
- et al.
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club
Hepatology
(2003) - et al.
Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis
Gastroenterology
(1997) - et al.
Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites
Gastroenterology
(1994) - et al.
Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis
Gastroenterology
(1996) Pharmacological treatment of portal hypertension: present and futur
J Hepatol
(1998)Evolving consensus in portal hypertension: report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension
J Hepatol
(2005)- et al.
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club
Hepatology
(1996) - et al.
Transjugular intra-hepatic portosystemic shunts for refractory ascites: a meta-analysis of individual patients data
Gastroenterology
(2007)
Cited by (162)
Development and validation of a medication-based risk prediction model for acute kidney injury in older outpatients
2024, Archives of Gerontology and GeriatricsManagement of Portal Hypertension
2022, Journal of Clinical and Experimental HepatologyPrognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era
2021, Clinics and Research in Hepatology and GastroenterologyCitation Excerpt :More, we found that cirrhosis was more severe during period 2 (higher MELD score) and particularly in patients with an inadequate secondary prophylaxis. This finding is probably related to the conclusions of emergent studies that cast the benefit of beta-blockers into question in patients with severe cirrhosis [37–39] and could explain the low rate of adequate secondary prophylaxis in the latter years. This shows that there may be confusion amongst physicians regarding the appropriate prophylaxis for large esophageal varices in decompensated cirrhosis, while the risk of AVB is the most important.
Management of the major complications of cirrhosis: Beyond guidelines
2021, Journal of Hepatology
- †
These authors contributed equally to this work.